News Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 18, 2021
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the appointment of...
-
Apr 10, 2021- Results further support the investigation of monotherapy seribantumab for the treatment of solid tumors uniquely driven by an NRG1 fusion in the ongoing Phase 2 CRESTONE study -
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the presentation by...
-
Apr 6, 2021- Results show seribantumab efficiently inhibited HER3 and the entire ERBB family signaling pathway and established a biologically effective dose range for tumors driven by an NRG1 fusion -
Elevation Oncology, a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the publication in...
-
Mar 16, 2021Clinical Trial Matching Collaboration Will Enhance Identification of Patients with Any Solid Tumor Harboring an NRG1 Gene Fusion Identified Using NeoGenomics' Advanced Gene Fusion Panels
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and NeoGenomics, Inc. (NASDAQ:NEO),...
-
Jan 6, 2021
Elevation Oncology , a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today that Shawn M....
-
Nov 18, 2020- $65M Series B Raise Led by New Investors venBio Partners and Cormorant Asset Management, with Participation by Boxer Capital of Tavistock Group, Janus Henderson, Samsara Biocapital, Vivo Capital, and All Existing Series A Investors -
Elevation Oncology , a clinical-stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today a Series B financing of
-
Oct 26, 2020- Inhibition of HER3 by seribantumab reduces tumor volume by 50-100% in preclinical in vivo models containing an NRG1 fusion -
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the presentation of...
-
Sep 30, 2020- Inclusion of the CRESTONE Study within the Selected Trials for Accelerated Rollout Program Will Enhance Patient Recruitment and Facilitate Local Site Participation for Patients with Tumors Harboring an NRG1 Gene Fusion -
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, and US Oncology Research, one of...
-
Jul 21, 2020- $32.5M Series A Financing Led by Aisling Capital, Vertex Ventures HC, Qiming Venture Partners USA, Driehaus Capital Management, and BVF Partners -
Elevation Oncology , a clinical stage biopharmaceutical company focused on the development of precision medicines for patients with genomically defined cancers, announced today the launch of the...